A
Anne V. Philips
Researcher at University of Texas MD Anderson Cancer Center
Publications - 20
Citations - 1383
Anne V. Philips is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Antigen & Immunotherapy. The author has an hindex of 11, co-authored 20 publications receiving 972 citations. Previous affiliations of Anne V. Philips include Mayo Clinic.
Papers
More filters
Journal ArticleDOI
PD-L1 Expression in Triple-Negative Breast Cancer
Elizabeth A. Mittendorf,Anne V. Philips,Funda Meric-Bernstam,Na Qiao,Yun Wu,Susan M. Harrington,Xiaoping Su,Ying Wang,Ana M. Gonzalez-Angulo,Argun Akcakanat,Akhil Chawla,Michael Curran,Patrick Hwu,Padmanee Sharma,Jennifer K. Litton,Jeffrey J. Molldrem,Gheath Alatrash +16 more
TL;DR: Using tissue microarrays containing 105 triple-negative breast cancer specimens, Mittendorf and colleagues show that 20% of the TNBC specimens express PD-L1, half have lost PTEN, and inhibitors of PI3K pathway decrease PD- l1 expression, providing a rationale for therapeutic targeting of PD- L1 for TNBC.
Journal ArticleDOI
Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells.
Victor Gall,Anne V. Philips,Na Qiao,Karen Clise-Dwyer,Alexander A. Perakis,Mao Zhang,Guy T. Clifton,Pariya Sukhumalchandra,Qing Ma,Sangeetha M. Reddy,Dihua Yu,Jeffrey J. Molldrem,George E. Peoples,Gheath Alatrash,Elizabeth A. Mittendorf +14 more
TL;DR: It is concluded that HER2-positive breast cancer patients that have been treated with trastuzumab may experience a more robust antitumor immune response by restimulation of T cells with the E75 peptide vaccine, thereby accounting for the improved disease-free survival observed with combination therapy.
Journal ArticleDOI
Breast cancer cell uptake of the inflammatory mediator neutrophil elastase triggers an anticancer adaptive immune response.
Elizabeth A. Mittendorf,Gheath Alatrash,Na Qiao,Yun Wu,Pariya Sukhumalchandra,Lisa S. St. John,Anne V. Philips,Haile Xiao,Mao Zhang,Kathryn Ruisaard,Karen Clise-Dwyer,Sijie Lu,Jeffrey J. Molldrem +12 more
TL;DR: An investigation of the pathobiologic basis for the prognostic significance of neutrophil elastase in a model of cyclin E-overexpressing breast cancer reveals a previously unknown mechanism of antitumor adaptive immunity that links cancer cell uptake of an inflammatory mediator to an effective cytolytic response against an important breast cancer antigen.
Journal ArticleDOI
The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy.
Adrienne G. Waks,Daniel G. Stover,Jennifer L. Guerriero,Deborah A. Dillon,William T. Barry,Evisa Gjini,Christina A. Hartl,Wesley T Lo,Jennifer Savoie,Jane E. Brock,Robert Wesolowski,Zaibo Li,Adrienne Damicis,Anne V. Philips,Yun Wu,Fei Yang,Amy Sullivan,Patrick Danaher,Heather Ann Brauer,Wafa Osmani,Mikel Lipschitz,Katherine A. Hoadley,Michael S. Goldberg,Charles M. Perou,Scott J. Rodig,Eric P. Winer,Ian E. Krop,Elizabeth A. Mittendorf,Elizabeth A. Mittendorf,Sara M. Tolaney +29 more
TL;DR: The immune microenvironment of HR+/HER2− tumors differs according to tumor biology, and this cohort of paired pre-/postchemotherapy samples suggests a critical role for immunosuppressive macrophage expansion in residual disease.
Journal ArticleDOI
Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer.
G. Travis Clifton,Diane F. Hale,Timothy J. Vreeland,Annelies T. Hickerson,Jennifer K. Litton,Gheath Alatrash,Rashmi Krishna Murthy,Na Qiao,Anne V. Philips,Jason Lukas,Jarrod P. Holmes,George E. Peoples,Elizabeth A. Mittendorf +12 more
TL;DR: In HER2 low-expressing breast cancer, no significant difference in DFS was seen in the intention-to-treat analysis; however, significant clinical benefit was seenin patients with TNBC, and these findings warrant further investigation in a phase III randomized trial.